Enhanced Dermatological Care to Reduce Rash and Paronychia in Epidermal Growth Factor Receptor (EGRF)-Mutated Non-Small Cell Lung Cancer (NSCLC) Treated First-line With Amivantamab Plus Lazertinib
研究单位：[1]Janssen Research & Development, LLC[2]City of Hope,Duarte,California,United States,91010[3]City of Hope Huntington Beach,Huntington Beach,California,United States,92648[4]City of Hope Orange County Lennar Foundation Cancer Center,Irvine,California,United States,92618[5]City of Hope Long Beach Elm,Long Beach,California,United States,90813[6]Cancer and Blood Specialty Clinic,Los Alamitos,California,United States,90720[7]Keck Hospital of USC,Los Angeles,California,United States,90033[8]USC Norris Oncology Hematology Newport Beach,Newport Beach,California,United States,92663[9]City of Hope South Pasadena,South Pasadena,California,United States,91030[10]Hope and Healing Care,Hinsdale,Illinois,United States,60521[11]Oncology Hematology Associates,Springfield,Missouri,United States,65807[12]Renown Regional Medical Center,Reno,Nevada,United States,89502[13]Hunterdon Hematology Oncology,Flemington,New Jersey,United States,08822[14]Clinical Research Alliance, Inc.,Westbury,New York,United States,11590[15]Regional Medical Oncology Center,Wilson,North Carolina,United States,27893[16]University Hospitals Cleveland Medical Center,Cleveland,Ohio,United States,44106[17]Virginia Cancer Specialists,Fairfax,Virginia,United States,22031[18]Valley Medical Center,Renton,Washington,United States,98055[19]Gundersen Health System,W. Salem,Wisconsin,United States,54669[20]Hospital Italiano de Buenos Aires,Buenos Aires,Argentina,C1199[21]IADT Instituto Argentino de Diagnostico y Tratamiento,Caba,Argentina,C1122[22]Centro Medico Austral,Capital Federal,Argentina,C1017[23]Hospital Italiano de La Plata,La Plata,Argentina,B1900AXI[24]Hospital Privado de la Comunidad,Mar del Plata,Argentina,B7602[25]Fundacao Doutor Amaral Carvalho,Jaú,Brazil,17.210-080[26]Fundacao Antonio Prudente A C Camargo Cancer Center,Sao Paulo,Brazil,01509 900[27]Associacao Feminina de Educacao e Combate ao Cancer Hospital Santa Rita de Cassia,Vitoria,Brazil,29043-260[28]Changzhou No 2 Peoples Hospital,Changzhou,China,213004[29]West China Hospital,Chengdou,China,610041[30]Sichuan Cancer Hospital,Chengdu,China,610041[31]The First Affiliated Hospital Sun Yat sen University,Guang Zhou,China,510080[32]Huizhou Municipal Central Hospital,Huizhou,China,516001[33]Fudan University Shanghai Cancer Center,ShangHai,China,200032[34]Hopital Nord,Marseille Cedex 20,France,13915[35]Hopital PASTEUR,Nice,France,06001[36]Institut Curie,Paris,France,75005[37]Universitaetsklinikum der RWTH Aachen,Aachen,Germany,52074[38]Kliniken Essen-Mitte,Essen,Germany,45136[39]Universitaetsklinikum Giessen und Marburg GmbH,Giessen,Germany,35392[40]Thoraxklinik am Universitatsklinikum Heidelberg,Heidelberg,Germany,69126[41]Klinikum Kassel GmbH,Kassel,Germany,34125[42]Chungbuk National University Hospital,Cheongju-si,Korea, Republic of,28644[43]Gachon University Gil Hospital,Incheon,Korea, Republic of,405-760[44]Severance Hospital Yonsei University Health System,Seoul,Korea, Republic of,03722[45]Hospital Pulau Pinang,Georgetown,Malaysia,10450[46]University Malaya Medical Centre,Kuala Lumpur,Malaysia,59100[47]Hospital Tengku Ampuan Afzan,Kuantan,Malaysia,25100[48]Hospital Umum Sarawak,Kuching,Malaysia,93586[49]Hosp. Univ. A Coruna,A Coruna,Spain,15006[50]Hosp. Gral. Univ. de Alicante,Alicante,Spain,03010[51]Hosp. Univ. Quiron Dexeus,Barcelona,Spain,08028[52]Hosp. Univ. Vall D Hebron,Barcelona,Spain,08035[53]Hosp. Univ. de Jaen,Jaen,Spain,23007[54]Hosp. Univ. Lucus Augusti,Lugo,Spain,27003[55]Hosp. Gral. Univ. Gregorio Maranon,Madrid,Spain,28007[56]Hosp. Regional Univ. de Malaga,Malaga,Spain,29010[57]Hosp. Ntra. Sra. De Valme,Sevilla,Spain,41014[58]National Taiwan University Hospital Hsin Chu Branch,Hsin Chu,Taiwan,30059[59]Chang Kung Memorial Hospital,Kaohsiung City,Taiwan,833[60]Taichung Veterans General Hospital,Taichung City,Taiwan,40705[61]National Taiwan University Hospital,Taip
研究目的：
The purpose of this study is to evaluate whether enhanced dermatologic management can reduce incidence of grade greater than or equal to (>=) 2 dermatologic adverse events of interest (DAEIs) when compared with standard-of-care skin management in participants with locally advanced or metastatic stage IIIB/C-IV epidermal growth factor receptor (EGFR)-mutated non-small cell lung cancer (NSCLC) treated first-line with amivantamab and lazertinib.
